Duaklir Pressair patents expiration

DUAKLIR PRESSAIR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6681768 ASTRAZENECA Powder formulation disintegrating system and method for dry powder inhalers
Aug, 2022

(1 year, 1 month ago)

US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
Apr, 2027

(3 years from now)

US10085974 ASTRAZENECA Dosage and formulation
Mar, 2029

(5 years from now)

US11000517 ASTRAZENECA Dosage and formulation
Mar, 2029

(5 years from now)

Duaklir Pressair is owned by Astrazeneca.

Duaklir Pressair contains Aclidinium Bromide; Formoterol Fumarate.

Duaklir Pressair has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Duaklir Pressair are:

  • US6681768

Duaklir Pressair was authorised for market use on 29 March, 2019.

Duaklir Pressair is available in powder, metered;inhalation dosage forms.

Duaklir Pressair can be used as maintenance treatment of chronic obstructive pulmonary disease (copd).

The generics of Duaklir Pressair are possible to be released after 13 March, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Combination (NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)


More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic